Evaluative Clinical Sciences

Dr. Raphael’s clinical practice is entirely devoted to the care of patients with gastrointestinal malignancies, with a subspecialty focus on gastric, biliary tract, pancreatic and colorectal cancers.

Education:

• MD, 2012, Queen’s University, Canada
• FRCPC, 2017, internal medicine, University of Toronto, Canada
• FRCPC, 2018, medical oncology, University of Toronto, Canada
• Research fellowship, 2019, advanced cancer health services research, Queen’s University, Canada

Appointments and Affiliations:

• Associate scientist, Evaluative Clinical Sciences, Odette Cancer Research Program, Sunnybrook Research Institute
• Medical oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre
• Assistant professor, Division of Medical Oncology, Department of Medicine, University of Toronto

Research Foci:

• Cancer health services research
• Population-based outcomes research
• Organization and delivery of cancer care services in Canada

Research Summary:

Dr. Raphael’s research focus is on population-based cancer care. His research aims to identify ways to optimize the coordination and delivery of cancer care services, and to describe gaps in care, disparities in access to treatment, uptake of cancer therapies, and real-world toxicity and effectiveness. His research has already influenced practice guidelines globally, and led to a new quality metric that is routinely captured by Cancer Care Ontario (“time to initiating adjuvant chemotherapy”). Dr. Raphael was awarded the 2018–2019 Canadian Association of Medical Oncologists Research Fellowship to support his ongoing productive research portfolio.

Selected Publications:

See current publications list at PubMed.

1. Raphael MJ, Robinson AG, Booth CM, O’Donnell JO, Palmer M, Eisenhauer E, Brundage M. The value of progression-free survival as a treatment end point among patients with advanced cancer. JAMA Oncol. 2019 Sep 26. doi: 10.1001/jamaoncol.2019.3338. [Epub ahead of print]
2. Raphael MJ, Siemens DR, Booth CM. Would regionalization of systemic cancer therapy improve the quality of cancer care? J Oncol Pract. 2019 Jul;15(7):349–56.
3. Raphael MJ, Wei X, Karim S, Robinson AG, Bedard PL, Booth CM. Neurotoxicity among survivors of testicular cancer: a population-based study. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):653–8.
4. Raphael MJ, Chan DL, Law C, Singh S. Principles of diagnosis and management of neuroendocrine tumours. CMAJ. 2017 Mar 13;189(10):E398–E404.
5. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth, CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011 Jun 8;305(22):2335–42.

Related News and Stories:

• The value of progression-free survival as a treatment endpoint with Dr. Michael Raphael, Plenary Session podcast (Sept. 26, 2019)
• Tapping into the therapeutic expertise of high-volume cancer centers, Cancer Therapy Advisor (Aug. 23, 2019)